Pemigatinib
Generic name: Pemigatinib
Brand names: Pemazyre
Dosage form: oral tablet (13.5 mg; 4.5 mg; 9 mg)
Drug class:
Multikinase inhibitors
Usage of Pemigatinib
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery. Pemigatinib is usually given after your cancer has been treated with another medicine.
Pemigatinib is used only if your cancer has a specific genetic marker (an abnormal "FGFR2" gene). Your doctor will test you for this gene.
Pemigatinib was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to pemigatinib, but further studies are needed.
Pemigatinib may also be used for purposes not listed in this medication guide.
Pemigatinib side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Pemigatinib may cause serious side effects. Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of pemigatinib may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Pemigatinib
Tell your doctor if you have ever had:
You may need to have a negative pregnancy test before starting this treatment.
Both men and women using pemigatinib should use effective birth control to prevent pregnancy. Pemigatinib can harm an unborn baby or cause a miscarriage if the mother or father is using this medicine.
Keep using birth control for at least 1 week after your last dose. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using pemigatinib.
Do not breastfeed while using this medicine, and for at least 1 week after your last dose.
Relate drugs
- Afatinib
- Alecensa
- Alectinib
- Alunbrig
- Avapritinib
- Ayvakit
- Cobimetinib
- Cotellic
- Crizotinib
- Balversa
- Binimetinib
- Braftovi
- Brigatinib
- Capmatinib
- Ceritinib
- Dabrafenib
- Deucravacitinib
- Encorafenib
- Entrectinib
- Erdafitinib
- Fedratinib
- Futibatinib
- Gavreto
- Gilotrif
- Gilteritinib
- Infigratinib
- Inrebic
- Jakafi
- Koselugo
- Larotrectinib
- Litfulo
- Lorbrena
- Lorlatinib
- Lytgobi
- Mekinist
- Mektovi
- Midostaurin
- Momelotinib
- Nintedanib
- Ofev
- Ojjaara
- Pacritinib
- Pemazyre
- Pemigatinib
- Pexidartinib
- Pralsetinib
- Qinlock
- Retevmo
- Ripretinib
- Ritlecitinib
- Rozlytrek
- Ruxolitinib
- Ruxolitinib (Oral)
- Rydapt
- Selpercatinib
- Selumetinib
- Sotyktu
- Tabrecta
- Tafinlar
- Tepmetko
- Tepotinib
- Trametinib
- Truseltiq
- Turalio
- Ukoniq
- Umbralisib
- Vemurafenib
- Vitrakvi
- Vonjo
- Xalkori
- Xospata
- Zelboraf
- Zykadia
How to use Pemigatinib
Usual Adult Dose for Cholangiocarcinoma of biliary tract:
13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cyclesDuration of therapy: Until disease progression or unacceptable toxicity occurs.Comments:-FGFR 2 fusion positivity status must be known prior to initiation of therapy. -Assessment for FGFR 2 fusion positivity in tumor specimen should be performed with an appropriate diagnostic test.-This indication is approved under accelerated approval based on overall response rate and duration of response.Use: For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
Usual Adult Dose for Lymphoma:
13.5 mg orally once dailyDuration of therapy: Until disease progression or unacceptable toxicity occurs.Comments:-FGFR 1 rearrangement positivity status must be known prior to the initiation of therapy.-Assessment for FGFR 1 rearrangement positivity in tumor specimen should be performed with an appropriate diagnostic test.Use: For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement
Usual Adult Dose for Multiple Myeloma:
13.5 mg orally once dailyDuration of therapy: Until disease progression or unacceptable toxicity occurs.Comments:-FGFR 1 rearrangement positivity status must be known prior to the initiation of therapy.-Assessment for FGFR 1 rearrangement positivity in tumor specimen should be performed with an appropriate diagnostic test.Use: For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement
Warnings
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
What other drugs will affect Pemigatinib
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Other drugs may affect pemigatinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions